Telix Pharmaceuticals has initiated its Phase III ZIRCON-CP trial for TLX250-CDx, a PET imaging agent for renal cell carcinomas. The study, in collaboration with Grand Pharmaceutical Group, aims to further validate the effectiveness of the method in Chinese populations.